On October 7, 2024 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, reported seven oral and poster presentations will be featured at the 2024 AACR (Free AACR Whitepaper)-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"). The conference is being held October 23-25, 2024 in Barcelona, Spain (Press release, Revolution Medicines, OCT 7, 2024, View Source [SID1234647062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Two late-breaking presentations will feature new clinical data from patients treated for PDAC, including updated safety and efficacy data from the ongoing RMC-6236 monotherapy study and initial safety and antitumor activity data from the first-in-human monotherapy study of RMC-9805.

Details of the presentations are listed below:

Revolution Medicines Late Breaking Presentations:

Title: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Presenter: Brian Wolpin, M.D., M.P.H., Dana-Farber Cancer Institute
Abstract Number: 514LBA
Session: Late Breaking Posters
Date/Time: 12:00 p.m. – 7:00 p.m. CEST on October 23, 2024
9:00 a.m. – 5:30 p.m. CEST on October 24, 2024
9:00 a.m. – 3:00 p.m. CEST on October 25, 2024

Title: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal
adenocarcinoma (PDAC) from a Phase 1 study in advanced solid tumors
Presenter: David S. Hong, M.D., MD Anderson Cancer Center
Abstract Number: 502LBA
Session: Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug development
Date/Time 4:12 – 4:24 p.m. CEST on October 25, 2024

Additional Revolution Medicines Presentations:

Title: Selective Inhibition of Active KRAS G13C with RMC-8839 Reveals an Increased Dependence of Codon-13 KRAS-Mutant Cancers on Wild-Type RAS Isoforms
Presenter: Kyle Seamon, Ph.D.
Abstract Number: 92
Session: Molecular Targeted Agents
Date/Time: 12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23

Title: The RAS(ON) Multi-Selective Inhibitor RMC-6236 Synergizes with T Cell-Directed Immunotherapies to Extend Durability of Antitumor Activity in Preclinical RAS-Driven Cancer Models
Presenter: Elsa Quintana, Pharm.D., Ph.D.
Abstract Number: 307
Session: Translational Studies
Date/Time 9:00 a.m. – 5:30 p.m. CEST on Thursday, October 24

Title: Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRAS G12D-Driven Cancers
Presenter: Mallika Singh, Ph.D.
Abstract Number: 300
Session: Translational Studies
Date/Time: 9:00 a.m. – 5:30 p.m. CEST on Thursday, October 24

Collaborator Presentations:

Title: Preclinical Evaluation of RMC-7977, a Multi-Selective RAS(ON) Inhibitor, as a Therapeutic Strategy for KRAS-Mutant Cholangiocarcinoma
Presenter: Rodrigo Entrialgo-Cadierno, M.D., Universidad de Navarra
Abstract Number: 297
Session: Translational Studies
Date/Time 9:00 a.m. – 5:30 p.m. CEST on Thursday, October 24, 2024

Title: Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer
Presenter: Dr. Helen Adderley, The University of Manchester and The Christie NHS Foundation Trust
Abstract Number: 113
Session: New Drugs
Date/Time: 12:00 p.m. – 7:00 p.m. CEST on October 23, 2024

Investor Webcast
Revolution Medicines will host an investor webcast focused on PDAC data from the RMC-6236 and RMC-9805 monotherapy studies on Friday, October 25, 2024, following the AACR (Free AACR Whitepaper)-NCI-EORTC Symposium’s Late-Breaking Session. Details for the webcast will be forthcoming and available on the Investors section of the Revolution Medicines website at View Source

Additional updates on the company’s three RAS(ON) inhibitor clinical development programs will be provided later in the quarter.